Adma Biologics Stock Analysis

ADMA
 Stock
  

USD 2.69  0.01  0.37%   

The current rise in Adma Biologics short term price appreciation could raise concerns from investors as the firm is trading at a share price of 2.69 on 1,188,945 in volume. The company directors and management have successfully maneuvered the firm at convenient times to take advantage of all market conditions in September. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.73. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Adma Biologics partners.
Please continue to Trending Equities.
  
The Adma Biologics stock analysis report makes it easy to digest most publicly released information about Adma Biologics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Adma Biologics Stock analysis module also helps to analyze the Adma Biologics price relationship with some important fundamental indicators such as market cap and management efficiency.

Adma Biologics Stock Analysis Notes

About 69.0% of the company shares are held by institutions such as insurance companies. The book value of Adma Biologics was presently reported as 0.84. The company recorded a loss per share of 0.88. Adma Biologics had not issued any dividends in recent years. ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey. Adma Biologics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 527 people. For more info on Adma Biologics please contact Adam Grossman at 201 478 5552 or go to https://www.admabiologics.com.

Adma Biologics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Adma Biologics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Adma Biologics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Adma Biologics has very high historical volatility over the last 90 days
Adma Biologics has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 94 M. Net Loss for the year was (78.28 M) with profit before overhead, payroll, taxes, and interest of 1.17 M.
Adma Biologics currently holds about 69.5 M in cash with (105.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.35.
Roughly 69.0% of the company shares are held by institutions such as insurance companies
Latest headline from simplywall.st: Even though ADMA Biologics has lost US51m market cap in last 7 days, shareholders are still up 107 percent over 1 year - Simply Wall St

Adma Biologics Upcoming and Recent Events

Earnings reports are used by Adma Biologics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Adma Biologics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of March 2022
Next Financial Report11th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Adma Biologics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Adma Biologics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Adma Biologics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Adma Biologics specific information freely available to individual and institutional investors to make a timely investment decision.
10th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
28th of June 2022
Unclassified Corporate Event
View
27th of June 2022
Financial Statements and Exhibits. Other Events
View
21st of June 2022
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
13th of June 2022
Other Events
View
11th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
25th of March 2022
Financial Statements and Exhibits. Other Events
View
24th of March 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View

Adma Biologics Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Adma Biologics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Adma Biologics backward and forwards among themselves. Adma Biologics' institutional investor refers to the entity that pools money to purchase Adma Biologics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Blackrock IncCommon Shares12.6 M24.9 M
Perceptive Advisors LlcCommon Shares11.5 M22.8 M
Boothbay Fund Management LlcCommon Shares10.4 M20.5 M
Vanguard Group IncCommon SharesM17.9 M
Nuveen Asset Management LlcCommon Shares7.2 M14.2 M
Stonepine Capital Management LlcCommon SharesM13.9 M
Magnetar Financial LlcCommon Shares6.9 M13.6 M
Note, although Adma Biologics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Adma Biologics Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 442.54 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Adma Biologics's market, we take the total number of its shares issued and multiply it by Adma Biologics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Adma Biologics Profitablity

Adma Biologics' profitability indicators refer to fundamental financial ratios that showcase Adma Biologics' ability to generate income relative to its revenue or operating costs. If, let's say, Adma Biologics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Adma Biologics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Adma Biologics' profitability requires more research than a typical breakdown of Adma Biologics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (83.27) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (60.88) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.61.

Management Efficiency

The entity has return on total asset (ROA) of (13.16) % which means that it has lost $13.16 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (65.38) %, meaning that it created substantial loss on money invested by shareholders. Adma Biologics management efficiency ratios could be used to measure how well adma biologics manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 5th of October, Adma Biologics shows the Downside Deviation of 4.19, mean deviation of 2.89, and Risk Adjusted Performance of 0.1684. Adma Biologics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We have collected data for nineteen technical drivers for Adma Biologics, which can be compared to its rivals. Please confirm Adma Biologics standard deviation, treynor ratio, downside variance, as well as the relationship between the information ratio and value at risk to decide if Adma Biologics is priced correctly, providing market reflects its regular price of 2.69 per share. Please also double-check Adma Biologics total risk alpha, which is currently at 0.6058 to validate the company can sustain itself at a future point.

Adma Biologics Price Movement Analysis

null. The output start index for this execution was zero with a total number of output elements of zero. The Triple Exponential Moving Average (T3) indicator is developed by Tim Tillson as Adma Biologics price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.
.

Adma Biologics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Adma Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Adma Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Adma Biologics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Adma Biologics Predictive Daily Indicators

Adma Biologics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Adma Biologics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Adma Biologics Forecast Models

Adma Biologics time-series forecasting models is one of many Adma Biologics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Adma Biologics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Adma Biologics Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Adma Biologics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Adma Biologics shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Adma Biologics. By using and applying Adma Biologics Stock analysis, traders can create a robust methodology for identifying Adma Biologics entry and exit points for their positions.
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey. Adma Biologics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 527 people.

Current Adma Biologics Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Adma Biologics analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Adma Biologics analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
5.7Strong Buy5Odds
Adma Biologics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Adma Biologics analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Adma Biologics stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Adma Biologics, talking to its executives and customers, or listening to Adma Biologics conference calls.
Adma Biologics Analyst Advice Details

Adma Biologics Stock Analysis Indicators

Adma Biologics stock analysis indicators help investors evaluate how Adma Biologics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Adma Biologics shares will generate the highest return on investment. By understating and applying Adma Biologics stock analysis, traders can identify Adma Biologics position entry and exit signals to maximize returns.
Quick Ratio3.01
Fifty Two Week Low1.0100
Revenue Growth81.30%
Shares Short Prior Month25.54M
Average Daily Volume Last 10 Day4.54M
Average Daily Volume In Three Month2.63M
Shares Percent Shares Out14.63%
Gross Margins6.98%
Short Percent Of Float15.24%
Forward Price Earnings-13.29
Float Shares159.76M
Fifty Two Week High2.9200
Enterprise Value To Ebitda-9.68
Fifty Day Average2.4484
Two Hundred Day Average1.9276
Enterprise Value To Revenue5.29
Please continue to Trending Equities. You can also try Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Complementary Tools for analysis

When running Adma Biologics price analysis, check to measure Adma Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adma Biologics is operating at the current time. Most of Adma Biologics' value examination focuses on studying past and present price action to predict the probability of Adma Biologics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Adma Biologics' price. Additionally, you may evaluate how the addition of Adma Biologics to your portfolios can decrease your overall portfolio volatility.
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Is Adma Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adma Biologics. If investors know Adma Biologics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adma Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Adma Biologics is measured differently than its book value, which is the value of Adma Biologics that is recorded on the company's balance sheet. Investors also form their own opinion of Adma Biologics' value that differs from its market value or its book value, called intrinsic value, which is Adma Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adma Biologics' market value can be influenced by many factors that don't directly affect Adma Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adma Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine Adma Biologics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adma Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.